DURAVYU misses LUGANO's primary endpoint
EyePoint's first pivotal Phase 3 wet AMD study did not meet its prespecified non-inferiority criterion. ⚑ Company-reported secondary and safety signals cannot replace that failed primary test, while the separate LUCIA trial remains outstanding.
The 60-second version
LUGANO, the first pivotal Phase 3 trial of DURAVYU 2.7 mg in wet AMD, did not meet its prespecified primary non-inferiority criterion.
Key points
- Reuters independently reported the same central outcome disclosed by EyePoint on August 17, 2026.
- Non-inferiority asks whether efficacy is no worse than an active control beyond a margin fixed in advance; missing the criterion means that claim was not established.
- Reducing repeated eye injections could ease wet AMD treatment burden, but durability cannot compensate for unproven preservation of efficacy.
- ⚑ EyePoint's favorable secondary, exploratory and safety observations are company-reported and cannot replace the failed primary test.
- The separate pivotal LUCIA trial remains outstanding and will need interpretation alongside LUGANO.
Verdict. LUGANO is a pivotal primary-endpoint failure. Complete data and LUCIA may refine the program's outlook, but neither ⚑ company-reported selective secondary signals nor a ⚑ company-reported topline safety characterization can rewrite this result.
Bottom lineThe pivotal claim was not established
EyePoint disclosed on August 17, 2026 that LUGANO, its first pivotal Phase 3 trial of DURAVYU 2.7 mg for wet age-related macular degeneration, did not meet the prespecified primary endpoint for non-inferiority. Reuters independently reported the same central result.
Trial designWhat non-inferiority means
A non-inferiority trial asks whether a new treatment's efficacy is no worse than an active control by more than a margin fixed before results are known. The goal is often to preserve enough efficacy while gaining another advantage, such as fewer treatment encounters.
| Criterion met | The analysis excludes a loss larger than the prespecified margin, supporting the planned non-inferiority claim. |
|---|---|
| Criterion not met | The analysis cannot exclude a loss beyond that margin; the planned primary claim is not established. |
| What failure does not prove | It does not by itself prove zero activity, exact equality, or how an individual patient would respond. |
Clinical contextWhy injection burden matters
Wet AMD commonly requires repeated injections into the eye and recurring clinic monitoring to control fluid and protect central vision. This creates logistical and treatment burden for patients, caregivers and clinics. A durable therapy could reduce that burden, but fewer injections are valuable only if vision preservation and disease control remain adequately demonstrated.
Durability can add value to maintained efficacy; it cannot replace maintained efficacy.
Evidence hierarchyWhy one positive secondary result is not a rescue
The primary endpoint and statistical rule are chosen in advance to answer the trial's main confirmatory question while controlling false-positive risk. Secondary endpoints examine additional outcomes; exploratory endpoints generate hypotheses. When many measures are tested, chance alone makes at least one favorable result more likely.
- A secondary endpoint has confirmatory weight only when the protocol's prespecified testing hierarchy or multiplicity plan supports it.
- An exploratory analysis can guide future research but usually cannot establish the efficacy claim the primary endpoint failed to demonstrate.
- Complete effect estimates, confidence intervals, missing-data methods and consistency across endpoints matter more than the direction of one selected result.
What remainsLUCIA is a separate pivotal test
The second pivotal Phase 3 study, LUCIA, remains outstanding. Its result will add an independent test of the program, but it must be interpreted together with LUGANO. A different result would call for examination of consistency, uncertainty, trial conduct and the complete statistical plan rather than erasing the first study.
Evidence boundaryWhat can be concluded now
The confirmed conclusion is that LUGANO did not establish its prespecified primary non-inferiority claim. ⚑ Company-reported secondary, exploratory and safety signals remain subordinate until the complete dataset is reviewed. This report explains study interpretation and is not medical advice.